Scholarlink

Background <p>Cardiovascular-kidney-metabolic (CKM) syndrome reflects the interplay of metabolic dysfunction, chronic kidney disease (CKD), and cardiovascular disease (CVD). However, the prognostic implications of CKM syndrome stages in this population remain unclear.</p> Methods <p>Data were drawn from the fasting subsample of NHANES III (1988–1994) and NHANES 1999–2018. A total of 2598 cancer survivors aged ≥ 20 years were included. Cox proportional hazards models accounting for the complex survey design were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).</p> Results <p>During a median follow-up of 7.92 years (IQR: 4.00–12.58), 1165 all-cause deaths, 352 CCD deaths, and 350 cancer deaths occurred. In fully adjusted models, compared with Stage 0, Stage 4 was associated with 3.48-fold higher all-cause mortality (HR = 3.48; 95% CI 2.62–4.63), 7.77-fold higher CCD mortality (HR = 7.77; 95% CI 4.21–14.32), and 2.55-fold higher cancer mortality (HR = 2.55; 95% CI 1.52–4.28). Advanced CKM syndrome was associated with elevated risks of all-cause, and cancer mortality. Sensitivity analyses confirmed the robustness of these findings.</p> Conclusion <p>Advanced CKM syndrome is independently associated with increased risk of all-cause, cardiovascular, and cancer mortality among U.S. cancer survivors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cardiovascular-kidney-metabolic syndrome and risk of all-cause and cause-specific mortality among cancer survivors: a population-based cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月15日

查看全文
  • Yumeng Liu,
  • Zhongguang Yang,
  • Yulin Yin

摘要

Background

Cardiovascular-kidney-metabolic (CKM) syndrome reflects the interplay of metabolic dysfunction, chronic kidney disease (CKD), and cardiovascular disease (CVD). However, the prognostic implications of CKM syndrome stages in this population remain unclear.

Methods

Data were drawn from the fasting subsample of NHANES III (1988–1994) and NHANES 1999–2018. A total of 2598 cancer survivors aged ≥ 20 years were included. Cox proportional hazards models accounting for the complex survey design were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).

Results

During a median follow-up of 7.92 years (IQR: 4.00–12.58), 1165 all-cause deaths, 352 CCD deaths, and 350 cancer deaths occurred. In fully adjusted models, compared with Stage 0, Stage 4 was associated with 3.48-fold higher all-cause mortality (HR = 3.48; 95% CI 2.62–4.63), 7.77-fold higher CCD mortality (HR = 7.77; 95% CI 4.21–14.32), and 2.55-fold higher cancer mortality (HR = 2.55; 95% CI 1.52–4.28). Advanced CKM syndrome was associated with elevated risks of all-cause, and cancer mortality. Sensitivity analyses confirmed the robustness of these findings.

Conclusion

Advanced CKM syndrome is independently associated with increased risk of all-cause, cardiovascular, and cancer mortality among U.S. cancer survivors.